# A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

> **NCT06637371** · PHASE1 · RECRUITING · sponsor: **Amgen** · enrollment: 124 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** AMG 691
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06637371
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-16
- **Primary completion:** 2027-06-07
- **Final completion:** 2027-06-07
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06637371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06637371, "A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT06637371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*